The effects of ganglioside-monosialic acid in taxane-induced peripheral neurotoxicity in patients with breast cancer: a randomized trial. J Natl Cancer Inst 2020; 112: 55–62
Published: 15th June 2020
Authors: Su Y, Huang J, Wang S, Unger JM, Arias-Fuenzalida J, Shi Y et al.
Some 206 women with early breast cancer due to receive adjuvant taxane chemotherapy were randomly allocated ganglioside-monosialic acid (GM1). After one year, women who had GM1 had lower neurotoxicity scores (P<0.001) and les peripheral neuropathy (26.4 versus 97.8 per cent, P<0.001).Pubmed Link
You may also be interested in
Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer (CBCSG‐036): A randomized, controlled, multicenter trial. Cancer 2019; 125: 2185-2193
Authors: Yu K-D, Wu S-Y, Liu G-Y, Wu J, Di G-H, Hu Z et al.
West German Study Plan B Trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. J Clin Oncol 2019; 37: 799-808
Authors: Nitz M, Gluz O, Clemens M, Malter W, Reimer T, Nuding B et al.
Authors: Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J et al.
External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node negative breast cancer (RAPID): a randomized controlled trial. Lancet 2019; 394: 2165-2172
Authors: Whelan TJ, Julian JA, Berrang TS, Kim D-H, Germain I, Nichol AM et al.
Long term results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomized, phase 3, equivalence trial. Lancet 2019; 394: 2155-2164
Authors: Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA et al.
Use of anastrozole for breast cancer prevention (IBIS-II): long term results of a randomized controlled trial. Lancet 2020; 395: 117-122
Authors: Cuzik J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE et al.
Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor–positive early breast cancer: PALLET trial. J Clin Oncol 2019; 37: 178-189.
Authors: Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C et al.
Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor–positive breast cancer: long-term follow-up of the BIG 1-98 Trial. J Clin Oncol 2019; 37: 105-114.
Authors: Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen M-B, Ejlertson B, de Azambuja E et al.
Six versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet 2019; 393: 2599–2612.
Authors: Earl HM, Hiller L, Vallier A-L, Loi S, McAdam K, Hughes-Davies L et al.
Six months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet 2019; 393: 2591-2598.
Authors: Pivot X, Romieu G, Debled M, Pierga J-Y, Kerbrat P, Bachelot T et al.
Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH Phase 3 randomized clinical trial. JAMA Oncol 2019; 5:e190339.
Authors: Jackisch C, Stroyakovskiy D, Pivot X, Ahn JS, Melichar B, Chen SC et al.
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 2019; 393: 1440-1452.
Authors: Early Breast Cancer Trialists' Collaborative Group (EBCTCG)